The Cholesterol-ASCVD Connection: Is Your Patient at Risk?
Many patients with, or at high risk for, atherosclerotic cardiovascular disease (ASCVD) do not achieve guideline-recommended LDL-C targets despite currently available lipid-lowering therapies. The HEART-3 Study is evaluating whether a single administration of the gene-editing investigational medicine, VERVE-102, can durably lower LDL-C through targeted inactivation of the hepatic PCSK9 gene. VERVE-102 is being investigated as a potential treatment approach for patients with, or at risk for, ASCVD whose LDL-C remains elevated despite stable lipid-lowering therapy.
HEART-3 is a Phase 2, randomized, double-blind, placebo-controlled study evaluating VERVE-102, an investigational gene-editing medicine designed to durably lower low-density lipoprotein cholesterol (LDL-C) by turning off the PCSK9 gene in liver cells. The study is enrolling adult participants with, or at high risk for, atherosclerotic cardiovascular disease (ASCVD) whose LDL-C remains elevated despite stable lipid-lowering therapy.
The investigational medicine, VERVE-102, has not been approved by the FDA or any other regulatory authority for any use.
Primary Objective
To evaluate whether the investigational medicine, VERVE-102, is superior to placebo in lowering LDL-C
Primary Endpoint
Percent change in LDL-C from baseline
Participants who meet entry criteria will be randomized to receive one of the following:
Dose 1
of the investigational medicine, VERVE-102
Dose 2
of the investigational medicine, VERVE-102
Dose 3
of the investigational medicine, VERVE-102
Placebo
The investigational medicine, VERVE-102, and the placebo are both administered as a one-time IV infusion. Participants initially randomized to receive the placebo may be eligible to continue in a later part of the study.
Each participant will be monitored for at least 1 year after receiving VERVE-102. Participants who receive VERVE-102 will be asked to join a separate long-term follow-up study, which provides safety monitoring for a total of 15 years after their dose.
HEART-3 is a Phase 2, randomized, double-blind, placebo-controlled study evaluating VERVE-102 (LY4636581), a one-time investigational treatment designed to durably lower low-density lipoprotein cholesterol (LDL-C) by inactivating the PCSK9 gene in the liver, for adult participants who have, or at high risk for, ASCVD and an elevated LDL-C despite stable treatment.
VERVE-102 is investigational and has not been approved by the FDA or any other regulatory authority for any use.
Primary Objective
To evaluate if VERVE-102 is superior to placebo in lowering LDL-C
Primary Endpoint
Percent change in LDL-C from baseline to Day 90
Participants who meet entry criteria will be randomized in a 2:2:2:1 ratio to receive one of the following:
Dose 1 of VERVE-102
Dose 2 of VERVE-102
Dose 3 of VERVE-102
Placebo
VERVE-102 and the placebo are both administered as a one-time IV infusion. Participants initially randomized to receive the placebo may become eligible to receive VERVE-102 in a later part of the study.
Complete the form below to refer a potential candidate to the HEART-3 Study team. A member of the study team will follow up with you and/or your patient.